Wyeth Pharmaceuticals, Progenics drug has study setback - Philadelphia Business Journal:

All You Want to Know About Vinyl Siding
The companies are developing the drug to trear the gastrointestinal disorder knownas post-operativse ileus, or POI. On Tuesday, the Food and Drug Administrationnapproved Entereg, a POI drug developed by of Exton, Pa., and (NYSE GSK). Wyetj Pharmaceuticals of Collegeville, Pa., and Progeniczs of Tarrytown, N.Y., said they plan to review the studty data to determine whether to continue development ofthe drug, in intravenous form, for POI. The companies reportedf more successful study results from their midstaginbg testing of an oral form of The injectable form of Relistor has been approved to restors bowel function in patientswith late-stage advanced illnesses.
The FDA approved that use last Wyeth Pharmaceuticals is a division ofWyeth (NYSE:WYE) of Madison, N.J.